Welcome to our dedicated page for Unity Biotechnology news (Ticker: UBX), a resource for investors and traders seeking the latest updates and insights on Unity Biotechnology stock.
Unity Biotechnology, Inc. (NASDAQ: UBX) is a leading biotechnology company focused on developing innovative therapeutics aimed at extending human healthspan by targeting age-related diseases. The company's pioneering approach centers on creating senolytic medicines, which selectively eliminate senescent cells – cells that contribute to aging and various diseases. Unity's initial efforts are directed toward treating conditions such as osteoporosis, eye diseases, and pulmonary diseases.
Unity’s main drug candidates include:
- UBX1325: A promising treatment for age-related eye diseases, including diabetic macular edema (DME). UBX1325 recently demonstrated positive results in the Phase 2 ENVISION study, maintaining vision gains and significantly reducing anti-VEGF treatment needs in patients with wet AMD.
- UBX2089: A circulating hormone being studied for multiple neurological conditions.
- UBX2050: Another investigational drug aimed at age-associated diseases.
Recently, Unity announced the successful results from Part B of the Phase 2 ENVISION study for UBX1325, highlighting its safety and efficacy in maintaining visual acuity and reducing the treatment burden for patients with wet AMD who were not receiving optimal benefits from ongoing anti-VEGF therapy. The study showed that 40% of UBX1325-treated patients did not require anti-VEGF rescue through 48 weeks.
Unity's current focus is on its DME program, where UBX1325 showed a statistically significant improvement in visual acuity during the Phase 2 BEHOLD study. The company has initiated a Phase 2b study and plans to randomize the first patient in Q4 2023. Additional data from the ENVISION study is expected to be presented at upcoming medical conferences.
About the ENVISION Study: The Phase 2 ENVISION study is a multi-center, randomized, double-masked, active-controlled study evaluating the safety, tolerability, efficacy, and durability of UBX1325 in combination with aflibercept for patients with neovascular AMD.
For more detailed information, visit www.unitybiotechnology.com.
UNITY Biotechnology, Inc. (UBX) has announced the granting of stock-based awards to four new employees, covering a total of 453,000 shares. This decision was made between January 19 and February 2, 2021, in accordance with the UNITY 2020 Employment Inducement Incentive Plan. The plan was approved by the Board in March 2020 to attract new talent as a material inducement to commence employment. UNITY focuses on developing therapeutics aimed at reversing age-related diseases by targeting senescent cells.
UNITY Biotechnology has announced the appointment of Mike Sapieha, Ph.D., as chief scientific advisor, effective immediately. Sapieha, a leading expert in age-related ophthalmologic diseases, will enhance UNITY's research capabilities, particularly for its clinical candidate UBX1325. Additionally, Jason Damiano, Ph.D., and Nathan Guz, Ph.D., have been promoted to vice president roles. UNITY focuses on developing therapeutics to address aging diseases, notably through eliminating senescent cells. The latest advancements aim to transform treatments for ophthalmologic and neurologic conditions.
UNITY Biotechnology, Inc. (NASDAQ: UBX) announced the grant of stock-based awards covering 103,000 shares of common stock to two new employees from December 1 to December 15, 2020. These awards were made under the 2020 Employment Inducement Incentive Plan, approved by the Board in March 2020, aimed at attracting new talent. UNITY focuses on developing therapeutics to address aging-related diseases, particularly targeting senescent cells.
UNITY Biotechnology, Inc. (NASDAQ: UBX) announces leadership changes to enhance its focus on developing therapeutics for age-related diseases. Gilmore O’Neill has joined the board as chair of the science committee, emphasizing his extensive experience in clinical drug development. Nathaniel David will step down as president but remain on the board. These strategic changes aim to accelerate the clinical development of UBX1325 targeting diabetic macular edema and other neurological programs. Despite these advancements, the ongoing COVID-19 pandemic poses risks that could impact clinical trial timelines.
UNITY Biotechnology, Inc. (UBX) reported its Q3 2020 financial results, focusing on advancements in its cellular senescence programs. The company initiated a Phase 1 study for UBX1325 in diabetic macular edema, with initial results expected in H1 2021. Financially, as of September 30, 2020, cash equivalents totaled $132.2 million. Operating loss increased to $24.6 million from $22.4 million year-over-year, driven by higher R&D and G&A expenses. UNITY believes it has sufficient funds to sustain operations until mid-2022.
UNITY Biotechnology (NASDAQ:UBX) has announced that the first patient has been dosed in a Phase 1 study of UBX1325 for diabetic macular edema (DME). The study aims to evaluate the safety and pharmacokinetics of UBX1325, targeting the elimination of senescent cells to address DME complications. Approximately 15 patients will be enrolled, with initial safety results expected in early 2021. The CEO emphasized the potential of UBX1325 based on promising preclinical data, indicating its role in reducing vascular leakage and improving retinal function.
UNITY Biotechnology (NASDAQ:UBX) announced a corporate restructuring aimed at extending its cash runway through mid-2022 and prioritizing its resources towards cellular senescence programs in ophthalmology and neurology. The company plans to advance UBX1325 into Phase 1 clinical trials for diabetic macular edema, with initial patient dosing expected in H2 2020. A workforce reduction of approximately 30% is also planned, resulting in around 75 employees by year-end, to better align capital allocation with strategic goals.
UNITY Biotechnology (NASDAQ: UBX), focused on therapeutics addressing aging diseases, announced participation in three September investor conferences. These include the Citi 15th Annual BioPharma Virtual Conference on September 9, the Morgan Stanley 18th Annual Global Healthcare Conference on September 15 at 4:15 PM E.T., and the Cantor Fitzgerald Virtual Healthcare Conference on September 16 at 10:00 AM E.T. Webcasts of the events will be available on the Investor & Media section of UNITY’s website, with replays accessible for 90 days.
UNITY Biotechnology, a company focused on developing therapeutics to combat aging-related diseases, has appointed Lynne Sullivan as its permanent Chief Financial Officer, effective September 1, 2020. With over 20 years in the biotech sector, including significant experience at Biogen and roles on several boards, Sullivan's expertise is expected to enhance UNITY's financial strategy and business development. The company aims to innovate in therapeutics targeting conditions such as osteoarthritis and neurological diseases, although it faces potential risks due to the ongoing COVID-19 pandemic affecting clinical trials.
UNITY Biotechnology reported disappointing results from its Phase 2 study of UBX0101, aimed at treating painful osteoarthritis (OA) of the knee. The treatment failed to show a statistically significant difference compared to placebo at the 12-week primary endpoint. Consequently, UNITY will not advance UBX0101 into pivotal studies and will refocus on its senescence programs targeting ophthalmologic and neurologic diseases. The company anticipates completing the Phase 2 24-week data collection and the ongoing Phase 1b study in the latter half of 2020.
FAQ
What is the current stock price of Unity Biotechnology (UBX)?
What is the market cap of Unity Biotechnology (UBX)?
What is Unity Biotechnology's primary focus?
What diseases is Unity Biotechnology targeting?
What is UBX1325?
What were the latest results from the ENVISION study?
What are the current projects of Unity Biotechnology?
Where can I find more information about Unity Biotechnology?
What is the significance of senolytic medicines?
Has UBX1325 been approved for use?
What is the expected timeline for the ASPIRE study?
What partnerships does Unity Biotechnology have?
